Hossein Niknahad1, Reza Heidari2, Roya Firuzi3, Farzaneh Abazari3, Maral Ramezani3, Negar Azarpira4, Massood Hosseinzadeh5, Asma Najibi3, Arastoo Saeedi3. 1. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.; Pharmacology and Toxicology Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 3. Pharmacology and Toxicology Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 5. Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
Purpose: Accumulating evidence suggests that drug exposure during a modest inflammation induced by bacterial lipopolysaccharide (LPS) might increase the risk of drug-induced liver injury. The current investigation was designed to test if antimalarial drugs hepatotoxicity is augmented in LPS‑treated animals. Methods: Rats were pre-treated with LPS (100 µg/kg, i.p). Afterward, non-hepatotoxic doses of amodiaquine (25, 50 and 100 mg/kg, oral) and chloroquine (25, 50 and 100 mg/kg, oral) were administered. Results: Interestingly, liver injury was evident only in animals treated with both drug and LPS as estimated by pathological changes in serum biochemistry (ALT, AST, LDH, and TNF-α), and liver tissue (severe hepatitis, endotheliitis, and sinusoidal congestion). An increase in liver myeloperoxidase enzyme activity, lipid peroxidation, and protein carbonylation, along with tissue glutathione depletion were also detected in LPS and drug co-treated animals. Conclusion: Antimalarial drugs rendered hepatotoxic in animals undergoing a modest inflammation. These results indicate a synergistic liver injury from co-exposure to antimalarial drugs and inflammation.
Purpose: Accumulating evidence suggests that drug exposure during a modest inflammation induced by bacterial lipopolysaccharide (LPS) might increase the risk of drug-induced liver injury. The current investigation was designed to test if antimalarial drugs hepatotoxicity is augmented in LPS‑treated animals. Methods:Rats were pre-treated with LPS (100 µg/kg, i.p). Afterward, non-hepatotoxic doses of amodiaquine (25, 50 and 100 mg/kg, oral) and chloroquine (25, 50 and 100 mg/kg, oral) were administered. Results: Interestingly, liver injury was evident only in animals treated with both drug and LPS as estimated by pathological changes in serum biochemistry (ALT, AST, LDH, and TNF-α), and liver tissue (severe hepatitis, endotheliitis, and sinusoidal congestion). An increase in liver myeloperoxidase enzyme activity, lipid peroxidation, and protein carbonylation, along with tissue glutathione depletion were also detected in LPS and drug co-treated animals. Conclusion: Antimalarial drugs rendered hepatotoxic in animals undergoing a modest inflammation. These results indicate a synergistic liver injury from co-exposure to antimalarial drugs and inflammation.
Authors: A Mignon; N Rouquet; M Fabre; S Martin; J C Pagès; J F Dhainaut; A Kahn; P Briand; V Joulin Journal: Am J Respir Crit Care Med Date: 1999-04 Impact factor: 21.405
Authors: Jane F Maddox; Chidozie J Amuzie; Maoxiang Li; Sandra W Newport; Erica Sparkenbaugh; Christopher F Cuff; James J Pestka; Glenn H Cantor; Robert A Roth; Patricia E Ganey Journal: J Toxicol Environ Health A Date: 2010
Authors: Leila Moezi; Reza Heidari; Zahra Amirghofran; Ali Akbar Nekooeian; Ahmad Monabati; Ahmad R Dehpour Journal: Pharmacol Rep Date: 2013 Impact factor: 3.024